Anti-citrullinated protein antibodies: Role in pathogenesis of RA and potential as a diagnostic tool

Rheumatology International

Volumn 33, Issue 7, 2013, Pages 1669-1673

  Moeez, Sadaf ^a   John, Peter ^a   Bhatti, Attya ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Anti citrullinated protein antibodies (ACPAs); Diagnostic marker; Pathogenesis; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE EROSION; HUMAN; JOINT STABILITY; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CITRULLINE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84879696372     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2635-6     Document Type: Article

References (56)

1. Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26:201-204
2. Alamanos Y, Drosos AA (2005) Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4(3):130-136
3. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) Rheumatoid arthritis classification criteria: an American college of rheumatology/European League against rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580-1588
4. Andreas K, Lübke C, Häupl T, Dehne T, Morawietz L, Ringe J, Kaps C, Sittinger M (2008) Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther 10(1):R9
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1998) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
6. Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE, Tak PP, van de Stadt RJ, van der Laken CJ, Dijkmans BA, van Schaardenburg D (2010) Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 69(3):490-494
7. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP et al (2003) Influence of diseasemodifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48:46-53
8. Chibnik LB, Mandl LA, Costenbader KH, Schur PH, Karlson EW (2009) Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol 36(4):706-711
9. Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, Serre G (2008) Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 58(3):678-688
10. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, Wyns B, Vincent C, Mielants H, Boullart L, Serre G, Veys EM, De Keyser F (2004) Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 63:1587-1593
11. Del Val Del Amo N, Ibanez BR, Fito MC, Gutierrez PR, Loza CE (2006) Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 24:281-286
12. Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, Shlomchik MJ (2010) PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 11(6):535-542
13. Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30(11):1205-1213
14. Van der Helm-van AHM, Mil KNV, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res 7(5):R949-R958
15. Huizinga TW, Amos CI, van der Helm-van MAH, Chen W, van Gaalen FA, Jawaheer D, Schreuder GM, Wener M, Breedveld FC, Ahmad N, Lum RF, de Vries RR, Gregersen PK, Toes RE, Criswell LA (2005) Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52(11):3433-3438
16. Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F, Lum RF, Massarotti E, Weisman M, Bombardier C, Remmers EF, Kastner DL, Seldin MF, Criswell LA, Gregersen PK (2005) Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3. Arthritis Rheum 52(12):3813-3818
17. Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE, Parker A, Roubenoff R, Izmailova E, Coblyn JS, Weinblatt ME, Shadick NA (2008) Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis 67:358-363
18. Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085-1089
19. Kirwan JR, Quilty B (1997) Prognostic criteria in rheumatoid arthritis: can we predict which patients will require specific anti-rheumatoid treatment? Clin Exp Rheumatol 15:S15-S25
20. Klareskog L, Widhe M, Hermansson M, Ronnelid J (2008) Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol 20(3):300-305
21. Kokkonen H, Johansson M, Innala L, Jidell E, Rantapaa-Dahlqvist S (2007) The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther 9:R56
22. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Michael Holers VM (2006) Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116(4):961-973
23. Landewe RB (2003) The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 48:1-5
24. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41(5):778-799
25. Lee DM, Phillips R, Hagan EM, Chibnik LB, Costenbader KHMM, Schur PH (2009) Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. Ann Rheum Dis 68:201-208
26. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS (2007) Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 46:342-349
27. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120-126
28. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50(2):380-386
29. Nienhuis RL, Mandema E (1964) A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 23:302-305
30. Okamoto H, Kobayashi A (2011) Tyrosine kinases in rheumatoid arthritis. J Inflamm 8:21
31. Palosuo T, Tilvis R, Strandberg T, Aho K (2003) Filaggrin related antibodies among the aged. Ann Rheum Dis 62(3):261-263
32. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, Gregersen PK, Klareskog L, Rioux JD (2005) Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 77:1044-1060
33. Randall KL, Lambe T, Johnson A, Treanor B, Kucharska E, Domaschenz H, Whittle B, Tze LE, Enders A, Tanya L, Crockford TL, Bouriez-Jones T, Alston D, Cyster JG, Lenardo MJ, Mackay F, Deenick EK, Tangye SG, Chan TD, Camidge T, Brink R, Vinuesa CG, Batista FD, Cornall RJ, Goodnow CC (2009) Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat Immunol 10(12):1283-1291
34. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48(10):2741-2749
35. Raza K, Buckley CE, Salmon M, Buckley CD (2006) Treating very very early rheumatoid arthritis. Best Pract Res Clin Rheumatol 20(5):849-863
36. Saraux A, Berthelot JM, Chales G, Le Henaff C, Thorel JB, Hoang S et al (2001) Ability of the American college of rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 44:2485-2491
37. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43(1):155-163
38. Schuerwegh AJ, Ioan-Facsinay A, Dorjee AL, Roos J, Bajema IM, van der Voort EIH, Huizinga TWJ, Toes REM (2010) Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci 107(6):2586-2591
39. Scott DL, Coulton BL, Symmons DPM, Popert AJ (1987) Long-term outcome of treating rheumatoid arthritis: results after 20 years. The Lancet 329(8542):1108-1111
40. Smolen JS, Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2:473-488
41. Steiner G, Smolen J (2002) Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 4(Suppl 2):S1-S5
42. Suwannalai P, Scherer HU, van der Woude D, Ioan-Facsinay A, Jol-van der Zijde CM, van Tol MJ, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA (2011) Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Ann Rheum Dis 70(2):373-379
43. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, van Der HD, Landewe R, Kvien TK (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 67:212-217
44. Taneja V, Krco CJ, Behrens MD, Luthra HS, Griffiths MM, David CS (2007) B cells are important as antigen presenting cells for induction of MHC-restricted arthritis in transgenic mice. Mol Immunol 44(11):2988-2996
45. Torfs CP, King MC, Huey B, Malmgren J, Grumet FC (1986) Genetic interrelationship between insulin-dependent diabetes mellitus, the autoimmune thyroid diseases, and rheumatoid arthritis. Am J Hum Genet 38(2):170-187
46. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, Huizinga TW, Toes RE (2009) Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 60(7):1923-1931
47. Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engstrom A, Serre G, Burkhardt H, Thunnissen MM, Holmdahl R (2009) Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 206(2):449-462
48. van de Stadt LA, van der Horst AR, de Koning MH, Bos WH, Wolbink GJ, van de Stadt RJ, Pruijn GJ, Dijkmans BA, van Schaardenburg D, Hamann D (2011) The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 70(1):128-133
49. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR (2006) The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 54(4):1117-1121
50. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50(3):709-715
51. Van Venrooij WJ, Hazes JM, Visser H (2002) Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 60:383-388
52. van Venrooij WJ, van Beers JJ, Pruijn GJ (2008) Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 1143:268-285
53. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427-430
54. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der VEA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, Breedveld FC, Huizinga TW, Toes RE (2006) Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 54(12):3799-3808
55. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, Schreuder GM, Breedveld FC, Huizinga TW, de Vries RR, Toes RE (2005) Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 52:3058-3062
56. Young BJ, Leslie RD, Clark CJ, Hamblin TJ (1979) Anti-keratin antibodies in rheumatoid arthritis. Br Med J 2(6182):97-99